anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Administered at 0 min and 300 min. Combination of lauric acid, perilla oil and diindolylmethane was used as the dietary supplement.
We considered for the study all patients aged \>16 y undergoing elective or emergency colorectal surgery for cancer, diverticular disease, inflammatory bowel-disease or reversal of Hartmann's procedure. Both patients undergoing open and minimally invasive surgery were considered eligible.
The invention provides a medicine for treating erythema, eczema and ulceration of infants. The medicine fills in a gap in the prior art and is composed of arnebia root, frankincense, myrrh, catechu, dahurian angelica root, gentrin knotweed, milkvetch root and rhubarb root and rhizome. The invention is characterized in that after peanut oil is boiled, arnebia root, frankincense, myrrh, catechu, dahurian angelica root, gentrin knotweed, milkvetch root and rhubarb root and rhizome are added into the boiled peanut oil, then the above-mentioned Chinese herbal medicines are stood when the Chinese herbal medicines are brown, a proper amount of borneol is added when the Chinese herbal medicines are cooled to room temperature, then uniform stirring is carried out, and an obtained mixture is stood for subsequent usage. The medicine comprises 10 g of arnebia root, 6 g of frankincense, 6 g of myrrh, 8 g of catechu, 12 g of dahurian angelica root, 12 g of gentrin knotweed, 9 g of milkvetch root and 10 g of rhubarb root and rhizome. The medicine has the advantages of pain relieving, anti-inflammation, fast subsidence of a swelling, immediate action and a remarkable and fast effect. The medicine is a composition of pure traditional Chinese medicines, has no toxic and side effects on infants and can be used to replace talcum powder. External usage and oral administration of the medicine are both allowable. The Chinese herbal medicines used for the medicine are easily and widely available, so large scale production of the medicine can be realized.
Vascular endothelial growth factor A (VEGFA) plays a critical role as a potent angiogenesis factor and is highly expressed in hepatocellular carcinoma (HCC). Although the expression of VEGFA has been strongly linked to the aggressive nature of HCC, the specific posttranscriptional modifications that might contribute to VEGFA expression and HCC angiogenesis are not yet well understood. In this study, we aimed to investigate the epitranscriptome regulation of VEGFA in HCC. A comprehensive analysis integrating MeRIP-seq, RNA-seq, and crosslinking-immunprecipitation-seq data revealed that VEGFA was hypermethylated in HCC and identified the potential m6A regulators of VEGFA including a m6A methyltransferase complex component RBM15 and the two readers, YTHDF2 and IGF2BP3. Through rigorous cell and molecular biology experiments, RBM15 was validated as a key component of methyltransferase complex responsible for m6A methylation of VEGFA, which was subsequently recognized and stabilized by IGF2BP3 and YTHDF2, leading to enhanced VEGFA expression and VEGFA-related functions such as human umbilical vascular endothelial cells (HUVEC) migration and tube formation. In the HCC xenograft model, knockdown of RBM15, IGF2BP3, or YTHDF2 resulted in reduced expression of VEGFA, accompanied by significant inhibition of tumor growth closely associated with VEGFA expression and angiogenesis. Furthermore, our analysis of HCC clinical samples identified positive correlations between the expression levels of VEGFA and the regulators RBM15, IGF2BP3, and YTHDF2. Collectively, these findings offer novel insights into the posttranscriptional modulation of VEGFA and provide potential avenues for alternative approaches to antiangiogenesis therapy targeting VEGFA.
PURPOSE:To obtain a nontoxic bathing agent, containing an extract solution prepared by extracting the tree bark of Quillaia saponaria Mol. with a solvent consisting essentially of water or a lower alcohol and having great detergency with treating effects on dermatosis, atopic diseases or pimple and further sound sleep effects. CONSTITUTION:A bathing agent obtained by crushing the tree bark of Quillaia saponaria Mol. into a chip form, dipping the resultant chips in a solvent consisting essentially of water or a lower alcohol (e.g., methanol, ethanol, ethylene glycol or glycerol), heating the dipped chips, filtering the solvent to provide an extract solution (30-35% concentration) and containing the obtained extract solution therein. Since the above-mentioned bathing agent has great detergency and requires no washing of human bodies or bathtubs, the agent is greatly advantageous to persons of disabled bodies or the aged. The agent has treating effects on dermatosis, the ability to soundly sleep, etc., further prevention of reduction in hot water temperature and decrease in temperature difference between the upper and lower parts of hot water. The optimum amount of the agent used is 5-20cc expressed in terms of stock extract solution of the Quillaia saponaria Mol. based on 1m<3> hot water.
Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). Histones released during NETosis induces further formation of NETs, which is damaging to renal tissues and remote organs. Circulating trap-forming neutrophils directly injured the lung, while other dead tissue releases contributed to injury in other organs. Suppressing renal necroinflammation using inhibitors of NET formation, tubular cell necrosis or extracellular histones prevented kidney as well as remote organ injuries. Dual inhibition of neutrophil trap formation together with tubular cell necrosis had an additive protective effect. Preferably, damage to remote organs induced by AKI may be treated and/or prevented using anti-histone agents such as anti-histone IgG, recombinant activated protein C, or heparin, alone or in combination with other therapeutic agents, such as PAD inhibitors.
The safety and efficacy of ACUVUE® Theravision™ with Ketotifen was assessed in two double-masked, randomized, placebo-controlled clinical conjunctival allergen challenge (CAC) studies (CR-4483 and CR-4484) and two 12-week safety studies (CR-4490 and CR-4539). Patients in these studies had allergic conjunctivitis induced by an ocular allergen challenge and refractive ametropia (myopia and hyperopia) suitable for contact lens wear without more than 1.00 D of astigmatism. A total of 244 patients (488 eyes) were evaluate in the CAC studies. A total of 491 subjects were exposed to ACUVUE® Theravision™ with Ketotifen over a period of 12 weeks in the safety studies. These four studies demonstrated that ACUVUE® Theravision™ with Ketotifen was safe and more effective than placebo (1•DAY ACUVUE®) in preventing ocular itching in patients with allergic conjunctivitis. ACUVUE® Theravision™ with Ketotifen reduced ocular itching within 3 minutes and the response was sustained for up to 12 hours after lens insertion. Visual acuity was comparable between ACUVUE® Theravision™ with Ketotifen and 1•DAY ACUVUE®.

Not all refractive powers, design configurations, or lens parameters available were tested in clinical investigation of the lenses. Therefore, when selecting an appropriate lens design, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness and optic zone diameter. The potential impact of these factors on the patient's ocular health should be carefully weighed against the patient's need for refractive correction and prevention of itching associated with allergic conjunctivitis; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by the prescribing Eye Care Professional.
SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused similar to other opioids. Patients who continue to misuse, abuse, or divert buprenorphine products or other opioids should be provided with or referred for more intensive and structured treatment. Abuse of buprenorphine poses a risk of overdose and death. This risk is increased with the abuse of buprenorphine and alcohol and other substances, especially benzodiazepines.

SUBLOCADE is distributed through a restricted distribution system, which is intended to prevent the direct distribution to a patient. SUBLOCADE should only be dispensed directly to a healthcare provider for administration by a healthcare provider. It is supplied in prefilled syringes and is intended for administration only by subcutaneous injection by a healthcare provider. The entire contents of the prefilled syringe should be administered. After administration, a small amount (approximately 0.1 mL) of SUBLOCADE will remain in the needle and syringe and should be properly disposed of [see How Supplied/Storage and Handling ( 16)] . 

SUBLOCADE is injected as a liquid, and the subsequent precipitation of the poly (DL-lactide-co-glycolide) polymer creates a solid depot which contains buprenorphine. After initial formation of the depot, buprenorphine is released via diffusion from, and the biodegradation of, the depot. Clinical monitoring for evidence at the injection site of tampering or attempting to remove the depot should be ongoing throughout treatment. No accounts of subjects removing or attempting to remove the depot after administration of SUBLOCADE were reported in premarketing studies.
An ECG monitoring system for ambulatory patients includes a battery-powered ECG monitor which attaches to a patient to receive patient electrical signals. A processor continuously processes received ECG signals and stores the signals in memory in the monitor. A wireless transceiver in the ECG monitor transmits the processed ECG signals to a cellphone handset. The battery of the monitor is recharged when the monitor is properly positioned in a charging dock, during which time the ECG signals are sent to the cellphone handset. Preferably the cellphone handset is recharged by the charging dock at the same time. At the conclusion of recharging and data transfer the monitor performs a self-test. A light on the charging dock is illuminated if any of the operations performed while the monitor is docked is unsuccessful.
BACKGROUND: Stress urinary incontinence (SUI) significantly impacts women's health and imposes substantial mental and socio-economic burdens. Acupuncture and moxibustion, either alone or in combination with other non-surgical therapies, are recognized as effective treatments for SUI. This study aimed to assess the efficacy of various treatments for women with SUI using network meta-analysis (NMA).
METHOD: We systematically searched databases up until June 30, 2022, to identify relevant randomized controlled trials (RCTs) focusing on SUI in women. Subsequently, the quality of the included studies was assessed. NMA was performed using STATA 14.0 software.
RESULTS: A total of 31 RCTs involving 2922 participants were included in the analysis. A total of 18 treatment plans were identified. The treatment plan consisting of Moxibustion + PFMT + EB demonstrated the most significant reduction in ICIQ-UI-SF. Due to lack of consistency across studies, a NMA was not performed for the outcomes of effectiveness and the 1 h pad test.
CONCLUSIONS: The combined intervention of Moxibustion + PFMT + EB appears to be the most effective in reducing patients' reported symptoms and improving their quality of life. However, due to the limitations of the included studies, further high-quality RCTs are necessary to reinforce the current evidence.
High blood pressure is one of the most common health problems in this country. It can be caused by many factors, including stress, diet, diabetes, kidney disease, or obesity. In many people, there is no identifiable cause for their high blood pressure. If high blood pressure goes untreated, it can lead to heart failure, kidney failure, or stroke. Previous studies have shown that variations in three genes in chromosome 1-ATP1B1, RGS5, and SELE-cause some people to be more susceptible to developing high blood pressure. All three of these genes are involved in the development of proteins that play a role in regulating blood pressure, but it is not known exactly how variations in these genes affect blood pressure levels. This study will examine previously collected genetic samples from participants in two studies, the GenNet study and the Heredity and Phenotype Interaction (HAPI) Heart study. Study researchers will analyze the samples to identify and characterize variations in the ATP1B1, RGS5, and SELE genes. Results from this study may lead to more effective diagnostic and treatment options for people with high blood pressure.
Systems and methods for providing health information. A method for building a health predictive model is provided based on a plurality of electronic medical records representing a plurality of electronic medical cases each associated with a diagnosis of a medical condition. Symptom-attribute-value (SAV) ontology objects are extracted from the plurality of electronic medical records. A plurality of feature vectors respectively associated with the medical cases and at least partially based on the SAV ontology objects are generated. The health predictive model can be trained based on the feature vectors by using the diagnoses as category labels of the training. The method for providing health information can include presenting a probability vector by inputting a current feature vector into the health predictive model. The current feature vector can be based on responses received via a health conversation. Advantageously, personalized and highly relevant medical advice can be provided to a user.
PROBLEM TO BE SOLVED: To easily obtain the calcium ion-containing water capable of preventing the secondary infection in the inflammation of atopic dermatitis, effective for suppressing pruritus and burning sensation involved in the inflammation, thus useful as a skin cleansing/cleaning material, by mutual contact between chilled purified water and Ostreae testa powder. SOLUTION: (A) Chilled purified water is brought into contact with (B) Ostreae testa powder to effect leaching calcium ions. In this case, the component A pref. contain (C) a leaching and stabilizing auxiliary for the calcium ions (e.g. glycerol). Specifically, for example, the objective calcium ion-contg. water is pref. obtained by the following process: the component B containing about 60wt.% of calcium as the chief ingredient (e.g. obtained by current injection treatment of the pearl layer of oystershells) is brought into contact with the component A at about 0-10 deg.C to effect leaching calcium ions so as to be about 800-1,000ppm in concentration of the calcium ions.
The goal of this Phase II SBIR is to provide an efficient, engaging, and effective means to enhance parents' ability to reduce prevalence of alcohol use and consequences, and other substance use through the development and evaluation of REAL Parenting (RP). RP is a brief, interactive, self-paced, and digital curriculum for parents of high-school-aged adolescents, a frequently neglected population created from the evidence-based Parent Handbook,available in hard copy and DVD for college-bound youth only. The curriculum is needed because most parent-based prevention interventions target children or young adolescents, neglecting older adolescents, despite that fact that alcohol use increases in frequency and risk through midadolescence. Also, unlike other evidence-based parenting curricula, RP is brief, requires only the parents, does not require training, and can be used "on the go" through any digital device. This provides a market niche for the proposed project that addresses this curriculum gap through the innovative use of both technology and prevention science. This format will allow us to personalize or target parents based on their communication style and allows parents to customize their experience by choosing or clicking through the optional content. Personalization and customization are two essential engagement strategies for digital prevention interventions.
This invention relates to a sustained-release pharmaceutical composition for lung administration. It provides a sustained-release pharmaceutical composition containing a pharmacologically active substance. It controls the absorbability of the pharmacologically active substance. It also exerts the drug effect of the pharmacologically active substance for a long time in the case of administered into the lung. Namely, the sustained-release pharmaceutical composition for lung administration contains a pharmacologically active substance available in lung administration and carrageenan. It also provides the producing process and its usage.
Patients presenting to Vascular Surgical Units are usually multimorbid with increased cardiopulmonary risk. Autologous venous bypass is indicated in certain situations despite the longer duration of surgery. Optimizing patency has been an important goal since many years. Reconstruction problems are often based on intimal hyperplasia, which can be reduced via covering of the harvested vein as seen in previous studies.

This clinical trial will be conducted at our Division of Vascular Surgery and Endovascular Surgery at the University Hospital of Salzburg. Patients will be randomized into one of the two treatment options, which are a plain venous conduit or a by mesh covered venous conduit. During this clinical trial, the first follow-up will take place after 6 weeks; this corresponds to the usual follow-up interval. Due to the trial, further follow-ups will take place for each of the patients after 3 months, 6 months, 12 months, 2 years.
Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.
Type 2 diabetes is a metabolic disease that has reached epidemic proportions. The global incidence of this disease is estimated to increase from 120 million individuals to over 200 million by the year 2010. In type 2 diabetes, multiple metabolic defects contribute to hyperglycemia. These include insulin resistance, inadequate insulin secretion, and excessive hepatic glucose production. Nine classes of antihyperglycemic agents are currently approved for the treatment of type 2 diabetes (insulin, sulfonylureas, biguanides, alpha-glycosidase inhibitors, thiazolidinediones, glinides, glucagon-like peptide analogues, amylin analogues, and dipeptidyl peptidase 4 inhibitors). Each class acts by a unique mechanism on 1 or more of the metabolic defects.

Takeda Pharmaceutical Company Limited is developing TAK-379, a non-thiazolidinedione partial proliferator-activated receptor agonist for the treatment of type 2 diabetes mellitus. Study participation is anticipated to be approximately 4.5 months.
PURPOSE: To update the literature on peripheral optics and vision following intraocular lens (IOLs) implantation.
METHODS: We investigated how current IOLs influence peripheral visual function, peripheral optical quality, and visual perception and performance, in patients following cataract surgery. Peripheral vision is described as vision outside the central foveal region of the eye (beyond 4-5° of eccentricity). We systematically searched PubMed, Cochrane Central Register of Controlled Trials, Embase, and gray literature for relevant references. Randomized controlled trials and observational studies were eligible for inclusion. Finally, 47 studies with a total of 5963 participants were eligible for this review, of which 15 were included in the meta-analysis.
RESULTS: Regarding visual fields, the meta-analysis showed that the pooled estimate of mean deviation (MD) measured with perimetry tests (standard automated perimetry [SAP], short-wavelength automated perimetry [SWAP], and frequency doubling technology [FDT]) appears to be lower than the mean of healthy age-matched controls, regardless of IOL design. Results for pooled estimate show that localized defects (pattern standard deviation [PSD]) were higher than those in the healthy age-matched controls for FDT. We also collected evidence demonstrating that pseudophakia increases peripheral astigmatism and a myopic shift from 20° onward, leading to decreased peripheral image quality compared with that in phakic eyes. Patient-reported outcomes on peripheral vision showed a pooled score estimate of 95.19, indicating high satisfaction, and for the Steps & Stairs questions, a pooled score estimate at 0.23, indicating no to little difficulty seeing steps and stairs.
CONCLUSIONS: Peripheral image quality is degraded in eyes after cataract surgery. Nevertheless, whether this degradation leads to impaired visual function in the periphery requires further investigation.
ERCP will be performed under conscious sedation with intramuscular administration of diazepam 2.5-5.0 mg and pethidine 25-50 mg. If necessary, endoscopic sphincterotomy will be performed. A dilating bougie or balloon will be used to dilate the stenosis after sphincterotomy. After that, laser lithotripsy will be performed. Standard techniques (i.e., extraction basket, extraction balloon, or both) will be used for stone removal. A pancreatic duct stent or a nasopancreatic catheter will be inserted for temporary drainage if necessary.
INTRODUCTION: Dissociative identity disorder (DID) is characterised by, among others, subjectively reported inter-identity amnesia, reflecting compromised information transfer between dissociative identity states. Studies have found conflicting results regarding memory transfer between dissociative identity states. Here, we investigated inter-identity amnesia in individuals with DID using self-relevant, subject specific stimuli, and behavioural and neural measures.
METHODS: Data of 46 matched participants were included; 14 individuals with DID in a trauma-avoidant state, 16 trauma-avoiding DID simulators, and 16 healthy controls. Reaction times and neural activation patterns related to three types of subject specific words were acquired and statistically analysed, namely non-self-relevant trauma-related words (NSt), self-relevant trauma-related words from a trauma-avoidant identity state (St), and trauma-related words from a trauma-related identity state (XSt).
RESULTS: We found no differences in reaction times between XSt and St words and faster reaction times for XSt over NSt. Reaction times of the diagnosed DID group were the longest. Increased brain activation to XSt words was found in the frontal and parietal regions, while decreased brain activity was found in the anterior cingulate cortex in the diagnosed DID group.
DISCUSSION: The current study reproduces and amalgamates previous behavioural reports as well as brain activation patterns. Our finding of increased cognitive control over self-relevant trauma-related knowledge processing has important clinical implications and calls for the redefinition of "inter-identity amnesia" to "inter-identity avoidance".